🔍

Pfizer Limited (PFIZER)

📊 NSE: PFIZER 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 10:58

📢 Recent Corporate Announcements

Pfizer to Discontinue Minipress XL; to Receive USD 13.9M (~₹131.38 Cr) Lump Sum Compensation

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 07 Sep 2026, 11:25 AM

Pfizer Limited announced that it will discontinue the marketing, distribution, and sale of Minipress XL with effect from September 7, 2026, following parent Pfizer Inc. USA's decision to stop manufacturing the drug. In connection with the discontinuation, the company will receive a one-time lump sum payment of USD 13.9 million (~₹131.38 crore) from Pfizer Inc. USA. This compensation equates to approximately 20.1% of Pfizer Limited's Q1 FY27 revenue (₹653.17 crore in Jun 2026). While the lump sum will provide a short-term cash and profit boost, it permanently removes the revenue contribution of Minipress XL.

Discontinuation of marketing, distribution, and sale of Minipress XL effective September 7, 2026.
Decision driven by parent entity Pfizer Inc. USA discontinuing global manufacturing of the product.
Pfizer Limited to receive a lump sum payment of USD 13.9 million (~₹131.38 crore) from Pfizer Inc. USA.
Lump sum inflow of ₹131.38 crore represents ~20.1% of Jun 2026 quarterly revenue (₹653.17 crore).

💡 Watch the upcoming quarterly financial results for the accounting treatment of the ₹131.38 crore receipt and management commentary on the recurring revenue impact from discontinuing Minipress XL.

Pfizer Approves Rs 75 Per Share Final Dividend at 75th AGM

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 29 Jul 2026, 06:58 PM

Pfizer Limited's shareholders have officially approved all resolutions at the 75th Annual General Meeting held on July 28, 2026. The key highlight is the declaration of a final dividend of Rs 75 per equity share (750% of face value) for the financial year ended March 31, 2026. The voting results showed overwhelming support, with the dividend resolution receiving 99.9998% votes in favor. Additionally, shareholders ratified the appointment of Mr. P. Rengan as Director and the remuneration for cost auditors for FY 2026-27.

Final dividend of Rs 75 per equity share (750%) approved for FY 2025-26
Total of 1,05,890 shareholders were on record as of the July 17, 2026 record date
AGM voting turnout represented 81.96% of total shares, with 3,74,95,845 votes polled
Resolution for dividend declaration passed with 99.9998% of votes in favor
Promoter group holding of 63.92% (2,92,43,042 shares) voted entirely in favor of all resolutions

💡 Investors should note the official approval of the Rs 75 dividend and monitor the company's announcement regarding the specific payment date.

₹75 Dividend Approved at Pfizer Limited's 75th Annual General Meeting

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 28 Jul 2026, 07:06 PM

Pfizer Limited concluded its 75th AGM on July 28, 2026, where shareholders approved a dividend of ₹75 per equity share (750%). The meeting included the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. P. Rengan as Director. Managing Director Meenakshi Nevatia provided an overview of the company's performance, focusing on new product introductions and the specialty science portfolio. The company also ratified the remuneration for cost auditors for the 2026-27 financial year.

Approved a dividend of ₹75 per equity share (750%) for the financial year ended March 31, 2026
The 75th AGM was conducted virtually and concluded within 2 hours and 17 minutes
Management highlighted the strategy of increasing the share of global patented products, which reached 48.6% of sales
Ratified remuneration for Cost Auditors for the financial year ending March 31, 2027

💡 Monitor the dividend credit timeline and track the execution of the 'three-pronged strategy' involving specialty science and hybrid go-to-market models in upcoming quarterly results.

₹204.47 Cr Q1 Net Profit: Pfizer Reports 6.6% YoY Growth in Bottom Line

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 28 Jul 2026, 02:04 PM

Pfizer Limited reported a steady performance for the quarter ended June 30, 2026, with revenue from operations rising 8.3% YoY to ₹653.17 crore. Net profit increased by 6.6% to ₹204.47 crore, up from ₹191.75 crore in the corresponding quarter of the previous year. The company maintained strong profitability with a PAT margin of approximately 31.3%. Notably, there were no exceptional items this quarter, unlike the previous financial year which saw significant separation costs related to brand distribution shifts.

Revenue from operations increased to ₹653.17 crore from ₹603.05 crore in the year-ago quarter.
Net profit for the period stood at ₹204.47 crore, representing a 6.6% YoY growth.
Earnings Per Share (EPS) improved to ₹44.69 from ₹41.91 in June 2025.
Total expenses were well-managed at ₹421.33 crore, despite a ₹182.89 crore spend on stock-in-trade purchases.
Other income saw a decline to ₹44.84 crore compared to ₹67.17 crore in the same period last year.

💡 Investors should monitor the volume growth in legacy brands following the distribution agreement with Cipla and watch for the launch of new patented products from Pfizer's global portfolio.

CFO Amit Agarwal Resigns; Effective October 8, 2026

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 27 Jul 2026, 04:42 PM

Pfizer Limited has announced the resignation of Mr. Amit Agarwal from his positions as Executive Director – Finance and Chief Financial Officer (CFO). The resignation is effective from the close of business on October 8, 2026, as he intends to pursue a professional opportunity outside the company. Mr. Agarwal will also vacate his seat on the Board of Directors and three key committees, including Risk Management and CSR. The company has approximately two and a half months to manage the transition for this Key Managerial Personnel (KMP) role.

Resignation of CFO and Executive Director effective October 8, 2026
Transition period of 73 days provided from the announcement date of July 27, 2026
Cessation of membership in 3 board committees: CSR, Risk Management, and Board Administrative & Share Transfer
Company reports a strong financial position with a Net Worth of Rs 4,203 Cr and low Debt of Rs 70 Cr

💡 Watch for the announcement of a successor to the CFO role to ensure continuity in financial oversight and strategic execution.

< 1% Revenue Impact: Pfizer Clarifies Temporary Discontinuation of Premarin Cream

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Jul 2026, 06:13 PM

Pfizer Limited has clarified that the temporary discontinuation of Premarin Vaginal Cream in India is due to supply constraints for the imported product. The company stated that the product contributes less than 1% to its total revenue, ensuring that the financial impact on operations and profitability is immaterial. Management is actively exploring options to restore supply at the earliest. This clarification was issued on July 17, 2026, following a surveillance query from the National Stock Exchange regarding media reports.

Premarin Vaginal Cream contributes less than 1% to the total revenue of Pfizer Limited.
The product is imported and has been temporarily discontinued due to specific supply constraints.
The company confirmed the event is not a material disclosure under Regulation 30 of SEBI LODR.
Management is actively seeking options to restore the supply of the cream in the Indian market.

💡 Investors should treat this as a routine operational update with negligible financial impact. Focus should remain on the performance of the core specialty portfolio and legacy brands which drive the majority of the company's revenue.

Pfizer Limited Submits Routine Share Dematerialization Certificate for Quarter Ended June 30, 2026

🟡 NEUTRAL ⭐ 1/10

REGULATORY 📅 10 Jul 2026, 05:25 PM

Pfizer Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The document, issued by KFin Technologies Limited (the company's Registrar and Share Transfer Agent), confirms that share certificates received for dematerialization during the quarter ended June 30, 2026, have been processed. This is a standard administrative filing required by Indian market regulators to ensure the integrity of electronic shareholding records. There is no impact on the company's financial performance or business operations.

Compliance certificate issued for the quarter ended June 30, 2026
Confirmation provided by Registrar & Share Transfer Agent, KFin Technologies Limited
Document submitted to exchanges on July 10, 2026
Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018

💡 This is a routine procedural filing. Investors should monitor the company's upcoming Q1 FY27 earnings results for material financial updates.

Pfizer announces Rs 75 per share final dividend; Record date set for July 17, 2026

🟢 POSITIVE ⭐ 5/10

DIVIDEND 📅 07 Jul 2026, 05:14 PM

Pfizer Limited has announced a final dividend of Rs 75 per equity share for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine shareholder eligibility for this payout. The 75th Annual General Meeting (AGM) is scheduled for July 28, 2026, via video conferencing. Dividend payments are expected to commence on or after August 4, 2026, subject to shareholder approval at the AGM.

Final dividend declared at Rs 75 per equity share for FY 2025-26
Record date for dividend eligibility is July 17, 2026
75th Annual General Meeting scheduled for July 28, 2026, at 3:00 PM IST
Dividend payment to be processed on or after August 4, 2026
Remote e-voting period runs from July 24 to July 27, 2026

💡 Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA by the July 17 record date to ensure seamless dividend credit.

₹75 Final Dividend Recommended; 75th AGM Scheduled for July 28, 2026

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 06 Jul 2026, 10:21 PM

Pfizer Limited has issued a notice for its 75th Annual General Meeting (AGM) to be held on July 28, 2026. The Board has recommended a final dividend of ₹75 per equity share (750%) for FY 2025-26, with a record date of July 17, 2026. Key agenda items include the adoption of audited financial statements and the re-appointment of Mr. P. Rengan as Director. The company also disclosed transferring ₹1.65 crore in unclaimed dividends to the IEPF during the last financial year.

Final dividend of ₹75 per equity share (750% of face value) recommended for FY 2025-26.
Record date for dividend eligibility is July 17, 2026, with payment starting August 4, 2026.
Total shares held in the IEPF account stood at 4,34,170 as of March 31, 2026.
Unclaimed dividend amounting to ₹1.65 crore was transferred to the IEPF during the financial year.
Remote e-voting period is scheduled from July 24, 2026, to July 27, 2026.

💡 Investors should ensure their bank details are updated by the record date of July 17, 2026, to receive the ₹75/share dividend. Watch for the full Annual Report for updates on the global patented product pipeline.

Pfizer Limited Announces Trading Window Closure from June 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Jun 2026, 10:47 AM

Pfizer Limited has informed the stock exchanges that its trading window will be closed starting June 30, 2026, at the close of business. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter ending June 30, 2026. The window will remain shut for designated persons until 48 hours after the financial results are made public. This is a standard regulatory procedure for all listed Indian companies.

Trading window closure starts from the close of business on June 30, 2026.
The closure is related to the upcoming unaudited financial results for the quarter ending June 30, 2026.
The window will reopen 48 hours after the results are officially disclosed to the public.
The filing is a routine compliance measure under SEBI Insider Trading regulations.

💡 No action is required as this is a routine administrative filing. Investors should wait for the official announcement of the quarterly earnings date to assess the company's performance.

Pfizer Limited Appoints M/s. Kishore Bhatia & Associates as Cost Auditors for FY 2026-27

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 May 2026, 08:27 PM

Pfizer Limited has announced the appointment of M/s. Kishore Bhatia & Associates as the company's Cost Auditors for the financial year ending March 31, 2027. The decision was made by the Board of Directors during their meeting on May 12, 2026, following a recommendation from the Audit Committee. The appointed firm is a Mumbai-based practice with extensive experience in cost audits across the pharmaceutical and engineering sectors. The proposed remuneration for the auditors will be presented to shareholders for ratification at the upcoming Annual General Meeting.

Appointment of M/s. Kishore Bhatia & Associates (Firm Reg No. 000294) as Cost Auditors.
The appointment covers the financial year ending March 31, 2027.
Board approval was finalized on May 12, 2026, based on Audit Committee recommendations.
Auditor remuneration is subject to shareholder ratification at the next Annual General Meeting.

💡 This is a routine regulatory appointment required under the Companies Act and has no direct impact on the company's financial health. Investors should focus on the company's operational performance and upcoming quarterly results.

Pfizer Ltd Schedules 75th Annual General Meeting for July 28, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 May 2026, 08:17 PM

Pfizer Limited has announced that its 75th Annual General Meeting (AGM) will be held on Tuesday, July 28, 2026. The Board of Directors approved this schedule during their meeting on May 12, 2026. The meeting will be conducted virtually via Video-Conferencing or Other Audio-Visual Means in compliance with regulatory circulars. This is a standard administrative filing to inform the exchanges and shareholders of the upcoming annual event.

75th Annual General Meeting scheduled for July 28, 2026
Board of Directors approved the meeting date on May 12, 2026
Meeting to be held via Video-Conferencing (VC) or Other Audio-Visual Means (OAVM)
Compliance with Regulation 30 of SEBI (LODR) Regulations, 2015

💡 No immediate action is required; investors should wait for the detailed AGM notice to review the annual report and any proposed dividend resolutions.

Pfizer Ltd Announces Final Dividend of Rs 75 per Share; Sets Record Date for July 17, 2026

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 May 2026, 07:58 PM

Pfizer Limited has recommended a substantial final dividend of Rs. 75 per equity share for the financial year ended March 31, 2026. This represents a 750% payout on the face value of Rs. 10 per share. The company has officially fixed July 17, 2026, as the record date to determine the eligibility of shareholders for this payout. This announcement follows the board meeting held on May 12, 2026, reflecting a strong commitment to shareholder returns.

Recommended final dividend of Rs. 75 per equity share for FY 2025-26
Dividend payout represents 750% of the face value of Rs. 10 per share
Record date for determining dividend entitlement is fixed as July 17, 2026
The recommendation was finalized during the Board of Directors meeting on May 12, 2026

💡 Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day prior to the July 17 record date. The high absolute dividend amount makes it an attractive proposition for yield-seeking investors.

Pfizer Ltd Announces Rs 75 per Share Dividend; Reports Audited FY26 Results

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 May 2026, 07:52 PM

Pfizer Limited has recommended a substantial final dividend of Rs. 75 per equity share (750% of face value) for the financial year ended March 31, 2026. The company reported its audited financial results for FY26, maintaining a debt-free status with no outstanding long-term borrowings exceeding Rs. 1,000 crores. The dividend is subject to shareholder approval at the upcoming 75th AGM on July 28, 2026, with a record date set for July 17, 2026. This announcement reflects the company's strong cash position and commitment to shareholder returns.

Recommended a final dividend of Rs. 75 per equity share of Rs. 10 each (750%) for FY 2025-26.
Record date for dividend eligibility is fixed as Friday, July 17, 2026.
Dividend payment to be processed on or after August 4, 2026, post-AGM approval.
Confirmed non-applicability of 'Large Corporate' status with zero debt securities issued.
Appointed M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year 2026-27.

💡 Investors should note the record date of July 17, 2026, to qualify for the high dividend payout. The company's debt-free balance sheet and consistent dividend policy remain key positives for long-term portfolios.

Pfizer Ltd Recommends ₹75 Per Share Final Dividend for FY26

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 12 May 2026, 07:30 PM

Pfizer Limited's Board has recommended a substantial final dividend of ₹75 per equity share (750% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the company reported its audited financial results for FY26 and confirmed it remains debt-free with no long-term borrowings exceeding ₹1,000 crores. The 75th Annual General Meeting is scheduled for July 28, 2026, to seek shareholder approval for these items.

Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025-26.
Record date for dividend eligibility is Friday, July 17, 2026, with payment starting August 4, 2026.
Company confirmed it does not fall under the 'Large Corporate' category with zero debt securities issued.
Appointed M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year 2026-27.
75th Annual General Meeting to be held on July 28, 2026, via Video-Conferencing.

💡 Investors should maintain their positions to benefit from the high dividend payout, ensuring they hold shares before the July 17 record date. The company's debt-free status and consistent dividend policy reflect a strong and stable financial position.

View All PFIZER Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment, 'Pharmaceuticals'. In Q1 2020-21, Internal Medicine grew 13%, while Vaccines declined 23% and Hospital revenue fell 41%. Overall revenue for Q1 2020-21 was INR 515 Cr, a decline of 5.3% YoY from INR 544 Cr.

Geographic Revenue Split

Not disclosed in available documents, though the company operates primarily in India with service revenue of INR 10 Cr from Pfizer Inc. affiliates.

Profitability Margins

For FY 2025, Net Profit Margin was 33.65% (up from 25.14% in FY 2024) and Operating Profit Margin was 29.78% (up from 26.13% YoY). Q1 2020-21 Gross Margin was 65% (INR 327 Cr) vs 64% YoY.

EBITDA Margin

Operating Profit Margin for FY 2025 stood at 29.78%, representing a 13.9% YoY improvement from 26.13%. Q1 2020-21 profit from operations was INR 159 Cr, a 13% growth YoY.

Capital Expenditure

Not explicitly disclosed, but the company realized a net gain of INR 172.81 Cr from the sale of leasehold rights and buildings at Thane to Zoetis in FY 2025.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported N.A. for debt-equity and interest coverage ratios, indicating a debt-free status.

⚙️ Operational Drivers

Raw Materials

Not disclosed in available documents, though COGS (Cost of Materials Consumed and Purchases of Stock-in-Trade) represents approximately 35% of sales based on a 65% gross margin.

Key Suppliers

Pfizer Inc. affiliates provide services and likely product supply to Pfizer Limited.

Raw Material Costs

Cost of materials and stock-in-trade purchases represent approximately 35% of revenue (INR 176 Cr in Q1 2020-21). Procurement is influenced by product mix and global affiliate sourcing.

Logistics & Distribution

Freight and forwarding charges decreased in Q1 2020-21 due to lower sales volumes and movement restrictions.

📈 Strategic Growth

Expected Growth Rate

0.8-2%

Growth Strategy

Growth is driven by a three-pronged strategy: a specialty focus leveraging science, customized go-to-market solutions (hybrid FTE/contract models), and maximizing the share of the global product portfolio, which increased from 36.3% in 2016 to 48.6% in 2020.

Products & Services

Pediatric vaccines, Internal Medicine drugs (legacy brands), Oncology treatments, and Hospital-based specialty therapies.

Brand Portfolio

Upjohn (divesting), Consumer Healthcare (divesting), and Pfizer Global Portfolio products.

New Products/Services

The company is considering several new products from its patented global basket to drive future revenue contribution.

Market Expansion

Expansion of distribution and coverage through a hybrid sales model and increased 'feet on the ground' in targeted territories.

Market Share & Ranking

Pfizer Limited reported 3.9% growth (MAT June 2020) compared to MNC industry growth of 3.7%.

Strategic Alliances

Divestment of Thane assets to Zoetis for INR 172.81 Cr and ongoing service agreements with Pfizer Inc. affiliates.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and specialty portfolios; recovery was expected in 2021 following a 4.9% industry contraction in early 2020.

Competitive Landscape

MNCs grew at 3.7% vs Indian companies at 7.7% (MAT June 2020), indicating higher competition from local generic players.

Competitive Moat

Durable moat through a 70-year brand presence in India and a growing share of global patented products (48.6% of sales), which are harder to replicate than generics.